Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment.

"The authors declare that there is no conflict of interest."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants from the National High Level Hospital Clinical Research Funding (No. BJ-2022-127), CAMS Innovation Fund for Medical Sciences (CIFMS, No. 2021-I2M-C&T-A-020), the Beijing Committee of Science and Technology (No. Z181100001718162), the Natural Science Foundation of Beijing Municipality (No. 7222158), and the Beijing health science and technology achievements and appropriate technology promotion project (No. BHTPP2022094)."

"Ethics approval and consent to participate: This trial was registered on www.chictr.org.cn as ChiCTR1800018853. The study protocol was reviewed and approved by the institutional review boards of all participating institutions. Written informed consent for treatment administration and data collection was provided by all patients before any study-related procedures commenced. This study was conducted following the principles of the Declaration of Helsinki and the International Conference on Harmonization Harmonized Tripartite Guidelines for Good Clinical Practice."